Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
FWBI

FWBI - First Wave BioPharma, Inc. Stock Price, Fair Value and News

$0.99-0.04 (-3.88%)
Market Closed

Price Targets

FWBI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FWBI Price Action

FWBI RSI Chart

FWBI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

FWBI Valuation

Market Cap

2.8M

Price/Earnings (Trailing)

-0.18

EV/EBITDA

-1.52

Price/Free Cashflow

-1.41

MarketCap/EBT

-0.62

FWBI Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

FWBI Fundamentals

FWBI Earnings

Earnings (TTM)

-15.6M

Earnings Growth (Yr)

55.33%

Earnings Growth (Qtr)

-15.48%

FWBI Profitability

Return on Equity

-56.13%

Return on Assets

-11.56%

Free Cashflow Yield

-70.96%

FWBI Investor Care

Buy Backs (1Y)

29.28%

Diluted EPS (TTM)

-0.97

About First Wave BioPharma, Inc.

FWBI
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
 CEO
 WEBSITEfirstwavebio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES10

First Wave BioPharma, Inc. Frequently Asked Questions

FWBI is the stock ticker symbol of First Wave BioPharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Sun Nov 30 2025, market cap of First Wave BioPharma, Inc. is 2.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check FWBI's fair value in chart for subscribers.

The fair value guage provides a quick view whether FWBI is over valued or under valued. Whether First Wave BioPharma, Inc. is cheap or expensive depends on the assumptions which impact First Wave BioPharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for FWBI.